NeuroPace (NPCE) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for NeuroPace (NASDAQ: NPCE):

• 10/2/2026 – NeuroPace was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 9/21/2026 – NeuroPace had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/17/2026 – NeuroPace is now covered by KeyCorp. They set an “overweight” rating and a $18.00 price target on the stock.
• 9/17/2026 – NeuroPace is now covered by KeyCorp. They set an “overweight” rating and a $18.00 price target on the stock.
• 9/15/2026 – NeuroPace was given a new $21.00 price target by Raymond James Financial, Inc..
• 9/15/2026 – NeuroPace had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 8/17/2026 – NeuroPace had its “overweight” rating reaffirmed by Cantor Fitzgerald.

NeuroPace, Inc is a medical device company focused on developing and commercializing therapies for people with drug-resistant epilepsy. The company’s principal product is the RNS System, an implantable responsive neurostimulation device designed to monitor brain activity, identify abnormal electrical patterns associated with seizures, and deliver targeted stimulation intended to help prevent or reduce seizures.

The RNS System includes an implanted neurostimulator, leads placed in or on the brain, and external tools that support device programming, patient monitoring, and the collection of seizure-related data.